Article
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Journal for immunotherapy of cancer - 23 Oct 2019
Molinero Luciana, Li Yijin, Chang Ching-Wei, Maund Sophia, Berg Maureen, Harrison Jeanne, Fassò Marcella, O'Hear Carol, Hegde Priti, Emens Leisha A
Abstract excerpt
BACKGROUND: Metastatic TNBC (mTNBC) has a poor prognosis and few treatment options. The anti-PD-L1 antibody atezolizumab demonstrated clinical activity in mTNBC patients with PD-L1-positive tumor-infiltrating immune cells. The current study describes the tumor immune microenvironment (TiME) and genomic evolution across sequential therapies in a patient with a 31-year history of TNBC and a complete response (CR)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.